Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, discussed the potential sources of savings associated with the Medicare Drug Price Negotiation Program.
CMS's review and approval of formulary replacement of negotiated drugs will play an important role as a potential source of savings for prescription drugs, Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, explained.
Transcript
Can you discuss the sources of savings you foresee because of the Medicare Drug Price Negotiation Program (DPNP), and its impact on health insurance?
I see the sources of savings as 3, and I'm going to go through them. I think it's going to be very important to understand this as the negotiated prices are going to be published late this year, and we will be thinking about comparing those to the prices we were paying for drugs already.
I think one source of savings, which is the most immediate one, is the drugs that had net prices higher than the minimum statutory discounts set by the stature. So, drugs like that would be Stelara (ustekinumab) for instance, as we talked about in the session during ISPOR.
Then the second source of savings will be the ability of CMS to negotiate prices below the ceiling. I like to say that's an uncertain source of savings, as we don't know how much we're going to generate in savings from that, but [it's] expected, meaning we hope that they will be able to get drug prices negotiated prices below the ceiling.
And then the third source of savings that I think sometimes people don't realize, but I think it's important to think about it as we run numbers later this year, is the fact that we are going to index drug prices for 2026 on 2022 data. And it's going to be hard to estimate that because it’s going to be about the counterfactor, right? What do we think would have happened to net prices in those years absent negotiation? But the point is, and I'm saying that because I've tried to work through the numbers, what assumption you make for what would have happened to the net prices in those years actually makes a lot of difference, because we're talking about the annual rate that is 4 years. So, if you think that net prices could have increased by 3% every year, you get much more savings than if you think that the prices could have been stable. But maybe in some drug classes, net prices could have decreased because we know there's more competition.
I think that's an uncertain source of savings that probably we're not going to be able to have a good answer with data, because we just don't know what could have happened. But I just wanted to point out for the viewers, because I think what assumptions one grants on that sense, actually is going to make a huge difference on what one estimates in terms of savings.
Given the progress made so far with the DPNP, what potential implications do you see for formulary coverage within Medicare Part D and its potential ripple effects on private health insurance plans?
I think they had some texts on the last guidance released right before ISPOR. I think it's still a little bit unclear how CMS is going to look and review on what they are going to approve in terms of formulary placement of negotiated drugs. It seems clear that they do not want Part D plans to disadvantage the negotiated drugs and they do not want them to be placed on tiers above other drugs within the class. I think it's harder to speak as of the effects on the private market. So I guess we'll have to wait and see what happens in the private market.
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Proposed SNAP Cuts Could Threaten Prevention for Cognitive Decline, Dementias
July 30th 2025Supplemental Nutrition Assistance Program (SNAP) benefits may slow cognitive decline in older adults, highlighting the importance of food assistance in combating Alzheimer disease and dementia risks.
Read More
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Proposed SNAP Cuts Could Threaten Prevention for Cognitive Decline, Dementias
July 30th 2025Supplemental Nutrition Assistance Program (SNAP) benefits may slow cognitive decline in older adults, highlighting the importance of food assistance in combating Alzheimer disease and dementia risks.
Read More
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More
2 Commerce Drive
Cranbury, NJ 08512